Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer

• ClinicalTrials.gov Identifier: NCT02929862
• Recruitment Status: Completed
• First Posted: October 11, 2016
• Last Update Posted: September 25, 2019
• Sponsor: Lycera Corp.
• Information provided by (Responsible Party): Lycera Corp.

Study Description

Brief Summary:

This is a Phase 1/2A study designed to evaluate the safety and tolerability of increased repeated doses of LYC-55716 in subjects with locally advanced or metastatic solid tumors.

Condition or disease	Intervention/treatment	Phase
Cancer	Drug: LYC-55716	Phase 1; Phase 2

Detailed Description:

Approximately 30 subjects across approximately 5 United States (US) sites will be enrolled in the Phase 1 portion of the study and approximately 69-84 subjects across approximately 15 US sites will be enrolled in the Phase 2A portion of the study.

The Phase 1 portion of the study will follow a 3 + 3 dose-escalation design to evaluate twice-daily (BID) administration of LYC-55716 for DLTs and to determine the MTD and the RP2D for further assessment in Phase 2A. A treatment cycle will consist of 28 days of treatment and subjects may continue to receive subsequent cycles of therapy as long as they do not have clinically significant progressive disease.

In the Phase 2A portion of the study, 69-84 subjects with locally advanced or metastatic solid tumors considered most likely to be responsive to a RORγ agonist will be enrolled and treated at the MTD or RP2D.

Six cohorts of subjects with advanced cancer will be enrolled. Cohorts 1 to 3 will enroll 14 to 19 subjects per cohort. Tumor types include NSCLC (Cohort 1); gastric, esophageal and G-E junction adenocarcinoma (Cohort 2); and SCCHN (Cohort 3). Cohorts 4 to 6 will enroll up to 9 subjects per cohort. Tumor types include ovarian carcinoma (Cohort 4), renal cell carcinoma (Cohort 5), and urothelial carcinoma (Cohort 6).

Primary Study Objectives

Phase 1

• Evaluate the safety and tolerability of LYC-55716
• Determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D)

Phase 2A

• Determine the objective response rate according to response evaluation criteria in solid tumors (RECIST) v1.1.

Secondary Study Objectives

Phase 1

• Evaluate the activity of LYC-55716 by objective response according to RECIST v1.1.
• Determine the durability of any observed objective response

Phase 2A

• Determine the duration of response
• Determine progression-free survival (PFS) and overall survival (OS)
• Determine suitability of the RP2D for further study
• Characterize the pharmacokinetics (PK) of LYC-55716

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 119 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 1/2A Multicenter, Open-Label Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer
• Study Start Date: December 2016
• Actual Primary Completion Date: May 31, 2019
• Actual Study Completion Date: May 31, 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: Single Agent 55716	Drug: LYC-55716; For Phase 1, increasing doses of oral 55716 given BID for a 28 day cycle. For Phase 2A, the RP2D will be administered to patients for 28 day cycles.

Outcome Measures

Primary Outcome Measures :

1. Assess Tumor Activity [ Time Frame: 8 weeks ]
   Evaluated according to RECIST v1.1

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Subject is male or female and at least 18 years of age.
• Histological or cytological confirmation of advanced unresectable solid tumors, including those subjects who have progressed on standard anticancer therapy and for whom no further therapy that confers clinical benefit is available.
• Subject has an Eastern Cooperative Oncology Group (ECOG) score of 0 1 or Karnofsky Performance Status Score ≥ 70.
• Subject has a life expectancy of at least 12 weeks.

• Subject has adequate organ function as determined by the following laboratory values:

  • Absolute Neutrophil Count* ≥ 1,500/mm3 (≥ 1.5 x 109/L)
  • Platelets* ≥ 100,000/mm3 (≥ 100 x 109/L)
  • Lymphocytes ≥ 0.5 x 109/L
  • Hemoglobin* > 9.0 g/dL
  • Serum Creatinine or Creatinine Clearance** ≤ 1.5 x ULN, > 50 mL/min
  • Total Serum Bilirubin ≤ 1.5 x ULN (< 3.0 mg/dL if subject has Gilbert's syndrome)

  • Liver Transaminases (ALT/AST) ≤ 2.5 x ULN, ≤ 5.0 x ULN if liver metastases present

    • (* = without ongoing growth factor or transfusion support)
    • (** = calculated by Cockcroft and Gault's formula)
    • (ALT = alanine aminotransferase, AST = aspartate aminotransferase, ULN = upper limit of normal)

Exclusion Criteria:

• Subject has received an investigational drug in the 28 day period before the first dose of study drug (or within 5 half-lives if longer) or is currently participating in another interventional clinical trial.
• Subject has known symptomatic brain metastases or leptomeningeal involvement as assessed by CT scan or MRI. Subjects with stable asymptomatic brain metastases or leptomeningeal disease are eligible if they have not required new treatments for this disease in a 28 day period before the first dose of study drug, and anticonvulsants and steroids have not been administered for a period of 2 weeks prior to the first dose of study drug.
• Subject has not recovered from adverse reactions to prior cancer treatment or procedures (surgery, chemotherapy, immunotherapy, radiation therapy) to Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or better.
• Subject has a previous (within 5 years) or current malignancy other than the target cancer with the exception of curatively treated local tumors such as carcinoma in situ of the breast or cervix, basal or squamous cell carcinoma of the skin, or prostate cancer with Gleason Grade < 6 and prostate-specific antigen within normal range.

Modifications to Eligibility Criteria for the following specific tumor types:

Phase 2A will be limited to enrolling the following tumor types:

• NSCLC
• Gastric, Esophageal, and G-E Junction Adenocarcinoma
• SCCHN
• Ovarian Carcinoma
• Renal Cell Carcinoma
• Urothelial Carcinoma

Contacts and Locations

Locations

United States, Alabama

Lycera Investigational Site

Huntsville, Alabama, United States, 35805

United States, California

Lycera Investigational Site

Sacramento, California, United States, 95817

United States, District of Columbia

Lycera Investigational Site

Washington, District of Columbia, United States, 20007

United States, Florida

Lycera Investigational Site

Sarasota, Florida, United States, 34232

United States, Georgia

Lycera Investigational Site

Atlanta, Georgia, United States, 30322

Lycera Investigational Site

Augusta, Georgia, United States, 30912

United States, Illinois

Lycera Investigational Site

Chicago, Illinois, United States, 60611

United States, Minnesota

Lycera Investigational Site

Saint Cloud, Minnesota, United States, 56303

United States, Nebraska

Lycera Investigational Site

Omaha, Nebraska, United States, 68130

United States, New York

Lycera Investigational Site

New York, New York, United States, 10016

United States, North Carolina

Lycera Investigational Site

Durham, North Carolina, United States, 27710

United States, Oklahoma

Lycera Investigational Site

Oklahoma City, Oklahoma, United States, 73104

United States, Oregon

Lycera Investigational Site

Portland, Oregon, United States, 97213

United States, Pennsylvania

Lycera Investigational Site

Philadelphia, Pennsylvania, United States, 19111

United States, South Carolina

Lycera Investigational Site

Greenville, South Carolina, United States, 29605

United States, Tennessee

Lycera Investigational Site

Nashville, Tennessee, United States, 37203

United States, Texas

Lycera Investigational Site

Dallas, Texas, United States, 75230

Lycera Investigational Site

San Antonio, Texas, United States, 78229

United States, Virginia

Lycera Investigational Site

Charlottesville, Virginia, United States, 22908

Lycera Investigational Site

Fairfax, Virginia, United States, 22031

Sponsors and Collaborators

Lycera Corp.

More Information

• Responsible Party: Lycera Corp.
• ClinicalTrials.gov Identifier: NCT02929862
• Other Study ID Numbers: LYC-55716-1001
• First Posted: October 11, 2016
• Last Update Posted: September 25, 2019
• Last Verified: May 2018

Additional relevant MeSH terms:

Neoplasm Metastasis; Neoplastic Processes; Neoplasms; Pathologic Processes